Outlook Therapeutics, Inc. OTLK 深 沪
等待开盘 02-06 09:30:00 美东时间
0.39
-0.010
-2.50%
华盛通- 最 高0.42
- 今 开0.3971
- 成交量 121.75万股
- 最 低 0.39
- 昨 收 0.40
- 总市值 1732.36万
- 52周最高 3.39
- 市盈率 静 --
- 换手率 2.74%
- 52周最低 0.39
- 委 比 -65.38%
- 总股本 4441.95万
- 历史最高 219.20
- 量 比 0.80
- 振 幅 7.50%
- 历史最低 0.39
- 每 手 1
- 风险率 0.50%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting
Outlook Therapeutics Inc. Announces Date for Upcoming Annual Stockholders Meeting Outlook Therapeutics Inc. will hold its 2026 Annual Meeting of Stockholders on March 10, 2026. During the meeting, stockholders will vote on the election of three directors, the ratification of the selection of KPMG LL
01-27 06:02
美股大行评级 | 潜在涨幅36.7%！LMRI获多家大行首予超配评级； 瑞银下调甲骨文目标价从325美元至280美元
今日重点评级关注：HC Wainwright & Co.：维持Assertio Holdings"买入"评级，目标价从3美元升至35美元；HC Wainwright & Co.：维持万达生物制药"买入"评级，目标价从20美元升至22美元
01-06 17:52
美股大行评级 | 杰富瑞上调百度目标价从159美元升至181美元；花旗下调京东目标价从44美元下调至37美元
今日重点评级关注：Ascendiant Capital：维持NRX Pharmaceuticals"买入"评级，目标价从47美元升至48美元；BTIG：维持Hudson Pacific Properties"买入"评级，目标价从4.75美元升至26美元
01-05 13:52
FDA Issues Complete Response Letter To Outlook Therapeutics' ONS-5010/LYTENAVA BLA For Wet AMD; FDA Has Again Recommended That Confirmatory Evidence Of Efficacy Be Submitted To Support The Application, However The FDA Has Not Indicated What Type Of Confirmatory Evidence Would Be Acceptable
Outlook Therapeutics, Inc. (NASDAQ:OTLK), a biopharmaceutical company focused on enhancing the standard of care for bevacizumab for the treatment of retina diseases, today announced that the U.S. Food and Drug
01-01 05:16
Outlook Therapeutics Provides Regulatory Update on U.S. Food and Drug Administration Review of ONS-5010/LYTENAVA™ (bevacizumab-vikg) for the Treatment of Wet AMD
FDA issued a Complete Response Letter (CRL) for Outlook Therapeutics' resubmitted ONS-5010/LYTENAVA™ BLA for wet AMD treatment. The agency noted that additional data did not alter its previous conclusion, requiring confirmatory efficacy evidence. Bob Jahr, CEO, expressed disappointment but reaffirmed commitment to securing U.S. approval. The company's efforts include exploring alternative approval pathways and expanding into Europe, where LYTENAV...
2025-12-31 21:15
Outlook Therapeutics Announces New Employment Inducement Grants
Outlook Therapeutics, Inc. (Nasdaq: OTLK) announced that its Compensation Committee granted stock options to purchase 150,000 shares of common stock with an exercise price of $2.01 per share to two new employees, effective December 19, 2025. These awards were made as inducements for the employees to join the company, in accordance with NASDAQ Listing Rule 5635(c)(4). The company focuses on enhancing care for retina diseases using bevacizumab, wit...
2025-12-26 22:00
美股大行评级 | 潜在涨幅498.16%！SurgePays Inc获Ascendiant Capital升目标价至9.75美元，维持"买入"评级
今日重点评级关注：Ascendiant Capital：维持SurgePays Inc"买入"评级，目标价从9.5美元升至9.75美元；Ascendiant Capital：维持Outlook Therapeutics"买入"评级，目标价从8美元升至10美元
2025-12-23 12:32
Ascendiant Capital Maintains Buy on Outlook Therapeutics, Raises Price Target to $10
Ascendiant Capital analyst Edward Woo maintains Outlook Therapeutics (NASDAQ:OTLK) with a Buy and raises the price target from $8 to $10.
2025-12-22 18:40
Outlook Therapeutics Reports Financial Results for Fiscal Year 2025
Outlook Therapeutics reported a net loss of $62.4M ($1.79 per share) for fiscal year 2025, with $1.4M in revenue from initial sales of LYTENAVA™ in Germany and the UK. The company saw reduced R&D expenses and increased SG&A costs due to the product launch. Cash reserves totaled $8.1M as of September 30, 2025. The FDA PDUFA date for ONS-5010 is December 31, 2025, and the company is expanding commercially in Europe and preparing for potential U.S. ...
2025-12-19 13:05
Outlook Therapeutics to Present at the Piper Sandler 37th Annual Healthcare Conference
Outlook Therapeutics' CEO, Bob Jahr, will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on December 2, 2025, at 10:00 AM ET. A live webcast of the chat will be available on the company's website, with a replay archived for 90 days. Management will also host one-on-one meetings with investors. Outlook Therapeutics focuses on developing LYTENAVA™ for treating retinal diseases, which is the first approved opht...
2025-11-24 14:05
